https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 Long-term disability trajectories in primary progressive MS patients: a latent class growth analysis https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:36042 Wed 29 Jan 2020 16:35:27 AEDT ]]> Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:33927 Wed 23 Jan 2019 15:30:44 AEDT ]]> Defining reliable disability outcomes in multiple sclerosis https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:22648 Wed 22 May 2019 14:50:34 AEST ]]> Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:27446 Tue 13 Oct 2020 19:11:18 AEDT ]]> Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:19533 95% of the identified indication bias. Slightly lower relapse incidence was found among patients treated with glatiramer acetate or subcutaneous interferon β-1a relative to intramuscular interferon β-1a and interferon β-1b (p≤0.001). No differences in 12-month confirmed progression of disability were observed. Conclusion: Small but statistically significant differences in relapse outcomes exist among the injectable immunomodulators. MSBase is sufficiently powered to identify these differences and reflects practice in tertiary MS centres. While the present study controlled indication, selection and attrition bias, centre-dependent variance in data quality was likely.]]> Sat 24 Mar 2018 08:02:06 AEDT ]]> Risk of relapse phenotype recurrence in multiple sclerosis https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:20329 Sat 24 Mar 2018 07:55:11 AEDT ]]> Predictors of long-term disability accrual in relapse-onset multiple sclerosis https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:24856 -22). On-therapy relapses carried greater burden than off-therapy relapses. Cumulative treatment exposure was independently associated with lower EDSS at 10 years (coeff=-0.86, p=1.3x10-9). Furthermore, pregnancies were also independently associated with lower EDSS scores over the 10-year observation period (coeff=-0.36, p=0.009).We provide evidence of long-term treatment benefit in a large registry cohort, and provide evidence of long-term protective effects of pregnancy against disability accrual. We demonstrate that high annualized relapse rate, particularly on-treatment relapse, is an indicator of poor prognosis.]]> Sat 24 Mar 2018 07:11:22 AEDT ]]> Association of inflammation and disability accrual in patients with progressive-onset multiple sclerosis https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:36719 Mon 24 Aug 2020 10:45:35 AEST ]]> Defining secondary progressive multiple sclerosis https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:25306 Mon 06 Mar 2023 17:55:37 AEDT ]]> Prediction of on-treatment disability worsening in RRMS with the MAGNIMS score https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46553 Fri 25 Nov 2022 11:33:34 AEDT ]]>